KTRA רווח למניה בשנים עשר החודשים האחרונים Kintara Pharma

Kintara Therapeutics brings together scientists to combat rare forms of cancer within a flexible environment. The company's 12-month specific profit level on this GURU.Markets chart reflects the asset's dynamics, where -0.49 is recorded as the baseline value. The business is currently integrating its vaccine portfolio following a merger, relying on external CRO and CMO contractors to conduct testing.
Kintara Pharma - פילוחים אנליטיים ומדדי מפתח (KTRA)

Annual net earnings per share determine the portion of actual income attributable to a single security. The current trailing twelve-month EPS for Kintara Therapeutics (KTRA) demonstrates the efficiency of business capitalization without accounting for share dilution. The workforce reduction at Kintara Therapeutics (KTRA) to facilitate a merger with TuHURA directly impacts cost minimization, which is reflected in the dynamics of this metric. Trend analysis helps avoid overpaying for the asset. This metric confirms the company's actual ability to accumulate profit.